PE20130603A1 - Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Info

Publication number
PE20130603A1
PE20130603A1 PE2013000161A PE2013000161A PE20130603A1 PE 20130603 A1 PE20130603 A1 PE 20130603A1 PE 2013000161 A PE2013000161 A PE 2013000161A PE 2013000161 A PE2013000161 A PE 2013000161A PE 20130603 A1 PE20130603 A1 PE 20130603A1
Authority
PE
Peru
Prior art keywords
liasa
pharmaceutical composition
composition containing
steroid inhibitor
steroid
Prior art date
Application number
PE2013000161A
Other languages
English (en)
Inventor
Masuo Yamaoka
Takahito Hara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130603(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20130603A1 publication Critical patent/PE20130603A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE ESTEROIDE C17,20 LIASA TAL COMO (+)-6-(7-HIDROXI-6,7-DIHIDRO-5H-PIRROLO[1,2-c]IMIDAZOL-7-IL)-N-METIL-2-NAFTAMIDA; Y B) UN AGONISTA DEL RECEPTOR DE GnRH, UN ANTAGONISTA DEL RECEPTOR DE GnRH O UN FARMACO DE ADRENOCORTICOHORMONA TAL COMO ACETATO DE LEUPRORELINA O PREDNISOLONA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER DE PROSTATA INDEPENDIENTE DE ANDROGENOS
PE2013000161A 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa PE20130603A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007280813 2007-10-29

Publications (1)

Publication Number Publication Date
PE20130603A1 true PE20130603A1 (es) 2013-05-30

Family

ID=40591618

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001841A PE20090931A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
PE2013000161A PE20130603A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008001841A PE20090931A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Country Status (17)

Country Link
US (2) US20100261689A1 (es)
EP (1) EP2205239A2 (es)
JP (1) JP5430576B2 (es)
KR (1) KR20100088144A (es)
CN (1) CN101909622B (es)
AR (1) AR069079A1 (es)
AU (1) AU2008319767B8 (es)
CA (1) CA2703780A1 (es)
CL (1) CL2008003198A1 (es)
IL (1) IL205368A (es)
MX (1) MX2010004405A (es)
NZ (1) NZ585473A (es)
PE (2) PE20090931A1 (es)
RU (1) RU2481107C2 (es)
SG (1) SG185930A1 (es)
TW (1) TWI426901B (es)
WO (1) WO2009057795A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
EP2709614A4 (en) * 2011-05-17 2015-04-15 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
US10201549B2 (en) 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505444A (ja) * 1996-02-14 2000-05-09 ヘキスト・マリオン・ルセル・インコーポレイテツド テストステロン５α―レダクターゼおよびＣ▲下１７―２０▼リアーゼの活性阻害剤としての１７β―シクロプロピル（アミノ／オキシ）４―アザステロイド
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
MY134929A (en) * 2000-11-17 2008-01-31 Takeda Pharmaceutical Novel imidazole derivatives, production method thereof and use thereof
US7662974B2 (en) * 2002-01-10 2010-02-16 Takeda Pharmaceutical Company Limited Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
EP1615944A4 (en) * 2003-04-01 2010-08-11 Harbor Biosciences Inc ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
CA2610343A1 (en) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Release-control composition
EP1861109A2 (en) * 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
CN104306977A (zh) * 2006-08-25 2015-01-28 库伽尔生物科技公司 治疗癌症的方法和组合物
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
WO2009057795A8 (en) 2010-05-14
AU2008319767B8 (en) 2014-01-09
AU2008319767A1 (en) 2009-05-07
CA2703780A1 (en) 2009-05-07
CN101909622A (zh) 2010-12-08
SG185930A1 (en) 2012-12-28
KR20100088144A (ko) 2010-08-06
AU2008319767A8 (en) 2014-01-09
AR069079A1 (es) 2009-12-30
EP2205239A2 (en) 2010-07-14
MX2010004405A (es) 2010-05-03
TWI426901B (zh) 2014-02-21
TW200927097A (en) 2009-07-01
NZ585473A (en) 2012-03-30
US20100261689A1 (en) 2010-10-14
AU2008319767A2 (en) 2010-06-17
JP2011502114A (ja) 2011-01-20
RU2481107C2 (ru) 2013-05-10
PE20090931A1 (es) 2009-08-03
JP5430576B2 (ja) 2014-03-05
US20140256693A1 (en) 2014-09-11
IL205368A (en) 2014-08-31
RU2010121765A (ru) 2011-12-10
CL2008003198A1 (es) 2009-12-18
AU2008319767B2 (en) 2013-12-19
IL205368A0 (en) 2010-12-30
WO2009057795A2 (en) 2009-05-07
WO2009057795A3 (en) 2009-07-09
CN101909622B (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
PE20191710A1 (es) Modulador del receptor de androgeno y usos de este
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
UA107782C2 (ru) Антагонисты рецепторов fgf-r4
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
EA201792520A3 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
ECSP077309A (es) Compuestos amido y sus usos como farmaceuticos
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CR10748A (es) Compuesto de indol
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
CL2010001624A1 (es) Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
SV2011003855A (es) Heteroarilos sustituidos
EP2513343A4 (en) METHODS AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
GB2474813A (en) Triterpenoid compounds and methods of use thereof
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
UA105920C2 (uk) ПОХІДНІ СПОЛУК СТЕРОЇДАЛ[3,2-с]ПІРАЗОЛУ З ГЛЮКОКОРТИКОЇДНОЮ АКТИВНІСТЮ
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.

Legal Events

Date Code Title Description
FD Application declared void or lapsed